---
figid: PMC4123459__nihms-531858-f0001
figlink: /pmc/articles/PMC4123459/figure/F1/
number: F1
caption: Lymphatic endothelial cell (LEC) markers shown to be variably expressed in
  Gorham tissues include cluster of differentiation (CD)-31 protein, lymphatic vessel
  endothelial hyaluronan receptor (LYVE)-1, and CD105. Growth factors stimulating
  (black arrows) LEC proliferation and macrophage activation in Gorham disease are
  shown (blue boxes) and include vascular endothelial growth factor (VEGF; though
  it may not have a direct effect on LECs in Gorham disease (dashed arrows)), VEGF-C,
  platelet-derived growth factor (PDGF)-BB, and basic fibroblast growth factor (bFGF).
  Binding of these ligands to their receptors—VEGF-receptor (R)-2, VEGFR-3, PDGFR-β,
  and FGFR—will trigger downstream signaling. Clinical inhibitors (orange boxes, red
  barred lines) of LEC surface receptor proteins and their ligands shown to affect
  disease progression in Gorham disease include humanized monoclonal antibody bevacizumab,
  thalidomide and interferon (IFN)-alpha. Imatinib mesylate (imatinib) inhibits signaling
  through the tyrosine kinase domain of PDGFR-β. Small molecule tyrosine kinase inhibitors
  (smTKI) that are now in development and in clinical trials may be able to block
  signaling through the tyrosine kinase domains of activated receptors or their downstream
  effectors. One promising agent—sirolimus—blocks the mTOR pathway, which is activated
  through the PI3K/Akt and Ras/Raf signaling pathways. However, there are many other
  signaling targets that may present potential therapeutic opportunities in Gorham
  disease. Radiation therapy also halts progression in Gorham disease (in part) by
  inhibiting LEC proliferation. Bisphosphonates inhibit increased osteoclast activity
  and the ensuing bone resorption.
pmcid: PMC4123459
papertitle: 'Novel molecular pathways in Gorham disease: Implications for treatment.'
reftext: Jeroen Hagendoorn, et al. Pediatr Blood Cancer. ;61(3):401-406.
pmc_ranked_result_index: '44665'
pathway_score: 0.9390224
filename: nihms-531858-f0001.jpg
figtitle: 'Novel molecular pathways in Gorham disease: Implications for treatment'
year: ''
organisms:
- Homo sapiens
ndex: 4eee1f0c-ded5-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4123459__nihms-531858-f0001.html
  '@type': Dataset
  description: Lymphatic endothelial cell (LEC) markers shown to be variably expressed
    in Gorham tissues include cluster of differentiation (CD)-31 protein, lymphatic
    vessel endothelial hyaluronan receptor (LYVE)-1, and CD105. Growth factors stimulating
    (black arrows) LEC proliferation and macrophage activation in Gorham disease are
    shown (blue boxes) and include vascular endothelial growth factor (VEGF; though
    it may not have a direct effect on LECs in Gorham disease (dashed arrows)), VEGF-C,
    platelet-derived growth factor (PDGF)-BB, and basic fibroblast growth factor (bFGF).
    Binding of these ligands to their receptors—VEGF-receptor (R)-2, VEGFR-3, PDGFR-β,
    and FGFR—will trigger downstream signaling. Clinical inhibitors (orange boxes,
    red barred lines) of LEC surface receptor proteins and their ligands shown to
    affect disease progression in Gorham disease include humanized monoclonal antibody
    bevacizumab, thalidomide and interferon (IFN)-alpha. Imatinib mesylate (imatinib)
    inhibits signaling through the tyrosine kinase domain of PDGFR-β. Small molecule
    tyrosine kinase inhibitors (smTKI) that are now in development and in clinical
    trials may be able to block signaling through the tyrosine kinase domains of activated
    receptors or their downstream effectors. One promising agent—sirolimus—blocks
    the mTOR pathway, which is activated through the PI3K/Akt and Ras/Raf signaling
    pathways. However, there are many other signaling targets that may present potential
    therapeutic opportunities in Gorham disease. Radiation therapy also halts progression
    in Gorham disease (in part) by inhibiting LEC proliferation. Bisphosphonates inhibit
    increased osteoclast activity and the ensuing bone resorption.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFB
  - MAPK3
  - VEGFA
  - IFNA8
  - IFNA5
  - IFNA7
  - FGFRL1
  - PGF
  - VEGFC
  - FGFR4
  - KRAS
  - IFNA16
  - IFNA4
  - PDGFB
  - PIK3R6
  - PIK3R5
  - PIK3R4
  - PIK3CA
  - FGFR2
  - IFNA6
  - IFNA1
  - IFNA2
  - RAF1
  - BRAF
  - PDGFD
  - TNF
  - VEGFD
  - MAPK1
  - PECAM1
  - FGFR1
  - FGFR3
  - IFNA14
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - ARAF
  - AKT3
  - NRAS
  - PDGFA
  - PDGFC
  - LYVE1
  - IFNA10
  - IFNA13
  - PIK3CB
  - ENG
  - AKT1
  - IFNA17
  - IFNA21
  - MTOR
  - HRAS
  - AKT2
  - MAP2K1
  - MAP2K2
  - Bisphosphonate
  - Thalidomide
  - Sirolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA8
  entrez: '3445'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA5
  entrez: '3442'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA7
  entrez: '3444'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: Ras/Raf
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA16
  entrez: '3449'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA4
  entrez: '3441'
- word: PDGF-BB
  symbol: PDGF_BB
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: VEGF-C
  symbol: VEGFC
  source: hgnc_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA6
  entrez: '3443'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA2
  entrez: '3440'
- word: Ras/Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras/Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PDGF-
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: TNFa
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: CD31
  symbol: CD31
  source: hgnc_alias_symbol
  hgnc_symbol: PECAM1
  entrez: '5175'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA14
  entrez: '3448'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Ras/Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Ras/Raf
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PDGF-
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: PDGF-
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF-
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: LYVE1
  symbol: LYVE1
  source: hgnc_symbol
  hgnc_symbol: LYVE1
  entrez: '10894'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA10
  entrez: '3446'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA13
  entrez: '3447'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: CD105
  symbol: CD105
  source: hgnc_alias_symbol
  hgnc_symbol: ENG
  entrez: '2022'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA17
  entrez: '3451'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA21
  entrez: '3452'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: Ras/Raf
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Mek
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: Mek
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
chemicals:
- word: Bisphosphonate
  source: MESH
  identifier: D004164
- word: Thalidomide
  source: MESH
  identifier: D013792
- word: Sirolimus
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4123459__F1
redirect_from: /figures/PMC4123459__F1
figtype: Figure
---
